Ebola GP investigational vaccine

Paused developmental vaccine candidates
Ebola Vaccine Details
Therapeutic area
Infectious disease
Status
Technology
Parasitic diseases
Ebola
 
Phase 1
Matrix-M™ adjuvant
Therapeutic area
Parasitic diseases
Infectious disease
Ebola
Status
 
Phase 1
Technology
Matrix-M™ adjuvant

About the candidate

Our Ebola glycoprotein (GP) investigational vaccine is expressed in insect cells using our core recombinant baculovirus technology. The investigational vaccine works in concert with the Matrix-M™ adjuvant to enhance the magnitude of the immune response.

Why it matters

Ebola virus (EBOV) causes a rare but serious illness that can have devastating consequences on a community. With a fatality rate of up to 90%,1 it is critical to develop effective vaccines to help control the spread of EBOV outbreaks.

  1. Ebola virus disease. WHO. Available at:https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease [Accessed 3 Sept 2021].